---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-046804"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:50:25.974589+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Fennec announces four PEDMARK abstracts accepted at 2026 ASCO meeting

## Summary
- Four abstracts evaluating PEDMARK accepted for presentation/publication at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
- Key poster: STS-J01 study on delayed sodium thiosulfate for cisplatin-induced ototoxicity in pediatric/adolescent patients.
- Other posters: randomized phase 1 trial in men with metastatic germ cell tumor; real-world feasibility in young adults; audiometric outcomes in head and neck cancer.
- Full abstracts will be available on ASCO website May 21, 2026 at 5:00 p.m. ET.

## SEC filing metadata
- accession: 0001104659-26-046804
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465926046804/0001104659-26-046804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465926046804/fencf-20260422x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-046804
- JSON: https://secwatch.observer/filing/0001104659-26-046804.json
- Plain text: https://secwatch.observer/filing/0001104659-26-046804.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.